Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003873 (rheumatoid arthritis)
 53,068 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors report the case of a 58 year old female patient with rheumatoid arthritis. About 4 hours after each intramuscular injection of Myochrysin (Sodium-auro-thiomalate 5%) she showed undesired reactions such as sialorrhea, nausea, vomiting, abdominal pain, diarrhea, apathy, weakness, head ache, breast swelling, perspiration, feeling of incident death. The following day these symptoms declined, the joint pain, however, increased. The reaction recurred with each of the 5 Sodium-auro-thiomalate injections, but not after injections of 5% Solganal (Aurothioglucose). It is supposed that these side effects are connected with the quick absorption of the Sodium-auro-thiomalate in aqueous solution. The Aurothioglucose in oil suspension would not cause such reactions after an intramuscular injection because of its slower absorption.
 ...
PMID:[Reactions against sodium-auro-thiomalate in the treatment of rheumatoid arthritis]. 11 3

A case of severe enterocolitis which occurred on initiation of chrysotherapy for rheumatoid arthritis is reported. The patient, a male aged 50 years, suffered from dramatic diarrhea for several weeks. Biopsy specimens from the stomach, ileum and colon revealed signs of inflammation. Later, general toxicodermia, mouth ulcers, blood eosinophilia and asymptomatic proteinuria were observed. After several months all the side effects disappeared. The toxicodermia was the most persistent.
 ...
PMID:[Toxic reactions to gold salts with severe enterocolitis in a patient with rheumatoid arthritis]. 13 87

Prorezid treatment was applied to 30 patients with rheumatoid arthritis. It was applied per os with a daily dose of 300 mg to 12 subjects; to 18-intravenous drop infusion with 5 per cent serum glucose--daily dose 400 mg. Oral administration total dose-7-8 g; infusion-10-12 g. Drop infusion administration proved to be more effective and especially the combination of the preparation with salycilates, pirazolon derivatives, minimal doses of corticosteroids and antibiotics. Favourable effect on articular syndrome was obtained in 20 patients (66.6%) about 2-3 and sometimes 4-6 weeks after the onset of the treatment. First the articular pain was attenuated, latter on--the morning stiffness (3-4 week), the movements in the joints involved were improved, the edema decreased towards the 4-6th weeks. A complete normalization of the laboratory indices was observed in none of those patients. In 10 of the patients (33.3%) no clinical improvement was attained in the course of the treatment. In four of them--the improvement developed 4-6 months later, with a longer drug administration. Prorezid preparation is with a low toxicity, with manifestation of transitory side effects in single patients--diarrhoea, mild leukopenia. Alopecia was not observed. Those properties make the drug suitable for application in patients with rheumatoid arthritis whose treatment with the rest applied drugs failed to give results.
 ...
PMID:[Treatment of rheumatoid arthritis with the immunosuppresive agent, prorezid]. 33 87

Generalized amyloidosis was diagnosed by light and electron microscopy in 4 of 5 monkeys (Macaca mulatta) that had a history of chronic arthritis or chronic intermittent diarrhea, or both. Clinical signs and lesions of arthritis in the monkeys were compatible with diagnostic criteria for rheumatoid arthritis. Shigella sp was cultured from 1 monkey, and 2 other monkeys had colonic lesions characteristic of shigellosis. At necropsy, gross changes attributed to amyloid were seen only in the liver. Amyloid deposits in the liver, spleen, mesenteric lymph nodes, kidney, heart, adrenal glands, and other organs were determined by staining reactions and fine structural characteristics.
 ...
PMID:Amyloidosis in rhesus monkeys with rheumatoid arthritis and enterocolitis. 41 71

Diclophenac sodium, Voltaren, has been tested against indomethacin and placebo in a four-week double-blind between-patient trial in 182 patients with rheumatoid arhritis. The ameliorating effect of Voltaren on the usual clinical parameters was comparable to that of indomethacin, while no significant changes were observed in the placebo group. Side effects during treatment with Voltaren and indomethacin appeared mainly form the gastrointestinal tract and from CNS. While side effects from the gastrointestinal tract were similar in the two groups, side effects from the CNS appeared significantly less frequent during treatment with Voltaren than during treatment with indomethacin. No skin reactions, diarrhoea or gastrointestinal bleeding were observed in either group. Long-term studies are needed to establish the place of Voltaren in the treatment of rheumatoid arthritis.
 ...
PMID:Diclophenax sodium (Voltaren) in rheumatoid arthritis: a double-blind comparison with indomethacin and placebo. 78 8

The aim of this study was in the first place to elucidate the tolerance of rheumatic patients to prolonged treatment with tolfenamic acid. 91 patients took part in the trial, most of them suffering from rheumatoid arthritis. The daily dose of tolfenamic acid was 600 mg and the trial lasted 6 months. The side-effects were usually slight: diarrhea occurred in 8, other gastrointestinal disturbances in 11, dysuria in 8 and other side-effects in 3 cases. Six patients broke off their treatment because of side-effects ascribed to tolfenamic acid. However, laboratory tests failed to show any significant changes caused by this drug. One case of reversible thrombopenia was seen in a patient who had also received gold treatment. On the whole, the clinical effect was found to be good, and tolfenamic acid appeared to be well suited for long-term symptomatic treatment of rheumatics.
 ...
PMID:Prolonged treatment with tolfenamic acid in inflammatory rheumatic diseases. 108 7

A review of the literature and report of a case of benign gastrocolic fistula indicate that epigastric pain is the most frequent early symptom. Later, the predominant symptoms are diarrhea, weight loss and feculent vomiting. Patients suffering from rheumatoid arthritis and taking steroids appear to be particularly at risk of developing a gastrocolic fistula. Barium enema is the most reliable method of demonstrating the fistula. Preferred management is a one-stage gastrocolic resection and primary anastomosis.
 ...
PMID:Gastrocolic fistula complicating benign gastric ulcer: case report and review of literature. 111 58

To clarify the kinetics of cell membrane and intracellular mediators in the process of auranofin (AF)-induced diarrhea, we perfused electrolyte solution containing the oral gold preparation AF, which is a treatment for rheumatoid arthritis, through the rat jejunum, and studied net water and electrolyte transport, Na+, K(+)-ATPase activity, and c-AMP and c-GMP concentrations in the jejunal mucosa. In addition, change in Ca+ concentration in isolated intestinal cells was evaluated using fura-2-acetoxyl-methyl ester. AF significantly suppressed water and electrolyte transport. Mucosal secretion was increased due to elevation of the intracellular Ca+ concentration early in the perfusion period, then due to reduction in the Na+, K(+)-ATPase activity, and increase in the c-AMP concentration late in the perfusion period. Therefore, these cell membranes and intracellular mediators are considered to be involved in the mechanism of AF-induced diarrhea.
 ...
PMID:[Experimental study of the mechanism of auranofin-induced diarrhea]. 131 15

Data from four double-blind studies of the treatment of patients with rheumatoid arthritis or osteoarthritis were combined. For 4 to 12 weeks, 747 patients received Arthrotec, a combination of 50 mg of diclofenac and 200 micrograms of misoprostol, and 754 patients received 50 mg of diclofenac; the drugs were given twice or three times daily. The five most commonly reported adverse events were abdominal pain by 23.2% of the diclofenac/misoprostol patients and 19.8% of the diclofenac patients; diarrhea by 19.9% and 11.3%; nausea by 11.8% and 6.5%; dyspepsia by 11.2% and 7.8%; and flatulence by 8.0% and 3.1%. Other adverse events, reported by similar proportions of both treatment groups, included headache, gastritis, dizziness, vomiting, and constipation. In the diclofenac/misoprostol-treated patients, the abdominal pain and diarrhea were rated mild in 30.6% and 24.3%, moderate in 49.1% and 51.4%, and severe in 20.2% and 24.3%. Serious adverse events occurred in eight of the diclofenac/misoprostol-treated patients and in 13 of the diclofenac-treated patients; 12.6% and 10.1%, respectively, were withdrawn from the study because of adverse events. Results of laboratory tests of hepatic and renal function were similar in the two treatment groups.
 ...
PMID:Overall safety of Arthrotec. 143 22

The toxicity profiles of 7 disease modifying antirheumatic drugs (DMARD) (hydroxychloroquine, intramuscular (im) gold, D-penicillamine, oral gold, methotrexate (MTX), azathioprine and cyclophosphamide) were evaluated in 2,479 patients with rheumatoid arthritis consecutively enrolled at 5 centers in the Arthritis, Rheumatism and Aging Medical Information System (ARAMIS) program. Incidence rates for side effects are reported as events/1000 patient-years. Our descriptive study revealed an individual profile of prevalent toxicities for each drug. Oral gold was characterized by substantial lower gastrointestinal (GI) toxicity (diarrhea 391 events/1000 patient-years, loose bowel movement 148, lower abdominal pain 76), MTX by hepatotoxicity (47) while D-penicillamine had the only clinically significant incidence of altered taste (40). MTX users reported the most mucosal ulcers (87), followed by oral gold (76), im gold (55) and D-penicillamine (38). Rash was frequently seen with gold compounds and D-penicillamine, while upper GI toxicity was common with immunosuppressive agents. Cyclophosphamide had 48% discontinuations within 6 months. MTX had the lowest discontinuation rate in the first 6 months, but then showed little difference from im gold. A preliminary similarity index was developed to compare the toxicity profiles of various DMARD. Close similarities were found between toxicity profiles of im gold and D-penicillamine, and between azathioprine and MTX. Oral gold had a unique toxicity pattern. Knowledge of these different toxicity patterns can enable more appropriate selection of agents for particular patients.
 ...
PMID:Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. 167 21


1 2 3 4 5 6 7 8 9 10 Next >>